Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HoFH Patients’ Varied Response to PCSK9 Inhibition

Arterioscler Thromb Vasc Biol; ePub 2017 Dec 28; Thedrez, et al

Residual low-density lipoprotein receptor (LDLR) expression is a major determinant of low-density lipoprotein cholesterol (LDL-C) levels and may drive their individual response to evolocumab, a recent study found. Lymphocytes were isolated from 22 HoFH patients in the TAUSSIG trial. 10 patients were true homozygotes (FH1/FH1) and 5 identical compound heterozygotes (FH1/FH2). Lymphocytes were plated with our without mevastatin, recombinant PCSK9 (rPCSK9), or a PCSK9-neutralizing antibody. Researchers found:

  • All HoFH lymphocytes had reduced cell surface LDLR expression compared with non-FH lymphocytes, for each treatment modality.
  • Lymphocytes from FH1/FH2 patients displayed the lowest LDLR expression levels followed by lymphocytes from FH1/FH2 patients.
  • Mevastatin increased, whereas rPCSK9 reduced LDLR expression.
  • Significant positive correlations were found between levels of LDLR expression and the percentage reduction in LDL-C on evolocumab treatment.

Citation:

Thedrez A, Blom DJ, Ramin-Mangata S, et al. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor). Implications for the efficacy of evolocumab. [Published online ahead of print December 28, 2017]. Arterioscler Thromb Vasc Biol. doi:10.1161/ATVBAHA.117.310217.

This Week's Must Reads

Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al

PCSK9 Inhibitors for Tx of Hypercholesterolemia, Ann Pharmacother; ePub 2018 Apr 1; Patel, et al

High-Intensity Statin Use and LDL-C Control, J Clin Lipidol; ePub 2018 Apr 26; Lamprecht Jr, et al

Improving Adherence with ASCVD Interventions, Clin Cardiol; ePub 2018 Apr 17; Fentanes, et al

Lipid Screening in Children with NAFLD, J Pediatr; ePub 2018 Apr 13; Harlow, et al

Must Reads in Hypercholesterolemia

Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al

PCSK9 Inhibitors for Tx of Hypercholesterolemia, Ann Pharmacother; ePub 2018 Apr 1; Patel, et al

High-Intensity Statin Use and LDL-C Control, J Clin Lipidol; ePub 2018 Apr 26; Lamprecht Jr, et al

Improving Adherence with ASCVD Interventions, Clin Cardiol; ePub 2018 Apr 17; Fentanes, et al

Lipid Screening in Children with NAFLD, J Pediatr; ePub 2018 Apr 13; Harlow, et al